For instance, in individuals with T2D and higher cardiovascular risk, SGLT2 (sodium-glucose co-transporter 2) inhibitors showing cardiovascular benefits,54 along with intensive lipid-lowering and antihypertensive medications, could be recommended to reduce CVD.44 Here, SLC5A2 is linked to type 2 diabetes mellitus.